Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by wasagastaron Jul 20, 2017 1:22pm
82 Views
Post# 26491433

RE:RE:RE:RE:I posted this in Washngton Post comments section

RE:RE:RE:RE:I posted this in Washngton Post comments section
Madheights wrote: Every word of PR is under scrutiny.  There can't be any hyberbole.  And anyone who is long should consider this as protection to their own equity.  When the reports come out, they will be nothing but facts no matter how great, perhaps good, or perhaps ugly.

In the meantime, the trading silence is indicative of the uncertainty that awaits us all......the forthcoming PP.  The ink on the deal is drying.  All that remains are relevant signitures.  The contractual details won't matter as the market will force the outcome upon us all.  And being that this is currently a very apprehensive market, the outcome may suddenly not be to our liking.


Alright I'll bite Madheights. You seem to have special knowledge of a financing. Do tell. Careful, you are under scrutiny as well.
Bullboard Posts